Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CorMedix (CRMD) EBITDA: 2012-2025

Historic EBITDA for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to $8,205.

  • CorMedix's EBITDA rose 142.11% to $8,205 in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.9 million, marking a year-over-year decrease of 83.81%. This contributed to the annual value of -$17.9 million for FY2024, which is 61.29% up from last year.
  • Per CorMedix's latest filing, its EBITDA stood at $8,205 for Q3 2025, which was up 260.22% from -$5,121 recorded in Q2 2025.
  • Over the past 5 years, CorMedix's EBITDA peaked at $8,205 during Q3 2025, and registered a low of -$17.9 million during Q4 2024.
  • Over the past 3 years, CorMedix's median EBITDA value was -$8,368 (recorded in 2024), while the average stood at -$5.0 million.
  • The largest annual percentage gain for CorMedix's EBITDA in the last 5 years was 142.11% (2025), contrasted with its biggest fall of 325.59% (2025).
  • Quarterly analysis of 5 years shows CorMedix's EBITDA stood at -$7.8 million in 2021, then fell by 4.78% to -$8.2 million in 2022, then slumped by 42.40% to -$9.8 million in 2023, then skyrocketed by 100.03% to -$17.9 million in 2024, then surged by 142.11% to $8,205 in 2025.
  • Its EBITDA was $8,205 in Q3 2025, compared to -$5,121 in Q2 2025 and -$6,090 in Q1 2025.